
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion is a commercial-stage healthcare technology company with ample cash runway and a strong commercial momentum evident in the partnerships with top academic institutions and the addition of Lanman Spinal Neurosurgery as a first private-practice site for its CLARITY trial. With 16 million chronic low back pain sufferers in the US each year and a rising tide of payors and providers testing Nociscan, the company has a strong potential for growth. Risks to our positive outlook include slower than expected enrollment in the CLARITY trial and results of the trial, as well as balance sheet risks and regulatory hurdles.
Bears say
Aclarion is showing increased traction in its Nociscan platform with strong growth in scan volume in both Q4 and full-year 2025. However, the company's revenues remain nominal and operating expenses continue to outpace revenues, indicating potential financial strains in the future. The higher share count also weighs on future earnings estimates.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares